1AD.AX AdAlta ASX jumps 25% to A$0.005 after hours 27 Feb 2026: Phase I readout
The 1AD.AX stock jumped 25.00% to A$0.005 in after hours trade on 27 Feb 2026, driven by renewed investor interest ahead of a Phase I AD-214 milestone. Volume rose to 2,704,385 shares, above the recent average of 8,042,214 shares, indicating short-term buying pressure. AdAlta Limited (1AD.AX) trades on the ASX in Australia and remains a small-cap biotechnology play with a market cap of A$652,797. We review the price move, key financials, and what the next clinical readout could mean for holders
Price action and session detail for 1AD.AX stock
AdAlta (1AD.AX) closed the regular session at A$0.004 and moved to A$0.005 after hours, a 25.00% rise. The intraday range was A$0.004–A$0.005 with volume 2,704,385, a relative volume of 0.34, showing elevated but not sustained market participation.
Catalyst: AD-214 Phase I timing and 1AD.AX stock reaction
The spike aligns with focus on the company’s lead i-body, AD-214, now in Phase I and an earnings announcement scheduled 02 Mar 2026. Clinical milestones tend to move micro-cap biotech names; traders are repositioning ahead of data that could change sentiment quickly. For company details see AdAlta’s website source
Financials, valuation and key metrics for 1AD.AX stock
AdAlta reports EPS -0.01 and PE -0.50, reflecting ongoing pre-commercial losses and research spending. Key measures include priceAvg50 A$0.00443, priceAvg200 A$0.00331, and book-value negatives; market cap stands at A$652,797. Current ratio 0.89 and cash per share A$0.00101 suggest limited liquidity relative to clinical timelines.
Technicals, liquidity and trading risks for 1AD.AX stock
Short-term indicators show momentum: ROC 25.00% and CCI 150.23 flagged as overbought, while ADX 8.23 signals no clear trend. Average daily volume is 8,042,214 shares, so intraday moves can be volatile on smaller volume days. Investors should expect wide bid-ask spreads and low institutional liquidity in this ASX-listed biotech.
Meyka AI grade and model forecast for 1AD.AX stock
Meyka AI rates 1AD.AX with a score out of 100: 72.10 (B+) — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a near-term central target of A$0.010 per share versus the current A$0.005, an implied upside of 100.00%, with a downside scenario near A$0.002 (model-based). Forecasts are model-based projections and not guarantees.
Sector context and peer comparison for 1AD.AX stock
AdAlta sits in the ASX Healthcare sector, Biotechnology industry, where large-cap peers trade at far higher multiples. The healthcare sector on ASX has average PE near 27.15, making micro-cap biotech valuations less comparable. Investors typically value AdAlta on clinical progress and partnership milestones rather than standard earnings multiples.
Final Thoughts
AdAlta (1AD.AX) delivered a clear after hours move on 27 Feb 2026, up 25.00% to A$0.005, as traders position for an AD-214 Phase I update. The stock’s fundamentals show negative EPS -0.01, limited cash per share A$0.00101, and a small market cap A$652,797, which combine to make the name high risk and high volatility on the ASX. Our Meyka AI model projects a central 12-month price target of A$0.010, implying 100.00% upside from the current price, while a downside case to A$0.002 implies -60.00%. These scenarios reflect binary clinical outcomes and low liquidity; they are model-based and not guarantees. For active traders, watch volume, ASX announcements, and the scheduled 02 Mar 2026 update. For longer-term investors, re-evaluate after the Phase I readout and track cash runway versus R&D spend. Find company filings on the ASX source and monitor our Meyka AI-powered market analysis platform for real-time updates and internal coverage at Meyka 1AD.AX page.
FAQs
Why did 1AD.AX stock rise after hours today?
1AD.AX stock rose 25.00% after hours on 27 Feb 2026 as investors positioned for a Phase I AD-214 update and showed increased buying with 2,704,385 shares traded.
What is the Meyka AI forecast for 1AD.AX stock?
Meyka AI’s forecast model projects a central target of A$0.010 versus current A$0.005, implying 100.00% upside. Forecasts are model-based projections and not guarantees.
Is 1AD.AX stock a buy after the move?
Meyka AI rates 1AD.AX 72.10 (B+) — BUY, but the stock carries high clinical and liquidity risk. Consider position size and wait for the Phase I readout before adding exposure.
Where can I find official company updates for 1AD.AX stock?
Official updates appear on AdAlta’s website and ASX notices. See the company site source and the ASX company page for filings and announcements.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.